^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PHLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2)

    i
    Other names: PHLPP2, PH Domain And Leucine Rich Repeat Protein Phosphatase 2, KIAA0931, PHLPPL, PPM3B, PH Domain Leucine-Rich Repeat-Containing Protein Phosphatase 2, Protein Phosphatase, Mg2+/Mn2+ Dependent 3B, PH Domain Leucine-Rich Repeat-Containing Protein Phosphatase-Like, PH Domain And Leucine Rich Repeat Protein Phosphatase-Like, PHLPP-Like
    Associations

    News

    Trials
    3ms
    TRIM46 promotes chemoresistance of ovarian cancer via activating PHLPP2/PI3K/AKT pathway. (PubMed, Biochem Cell Biol)
    Functional assays showed that TRIM46 promoted cisplatin (CDDP) chemoresistance...In summary, our study reveals that TRIM46 promoted chemoresistance via downregulating PHLPP2, leading to activating PI3K/AKT pathway. This study provides a novel potential target for ovarian cancer therapy.
    Journal
    |
    HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • PHLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • TRIM46 (Tripartite Motif Containing 46)
    |
    cisplatin
    9ms
    Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma. (PubMed, Am J Hematol)
    Gene expression signatures associated with late PDX passages (3rd-5th) were enriched with proliferation and metabolic reprogramming-related genes and predicted prognosis in an independent AITL series. Low PHLPP2 mRNA expression predicted poor prognosis (p = 0.05) and engineered PHLPP2 or TET2 loss in CD4+ T-cells showed enhanced PI(3)K activation, thus uncovering a therapeutic target for clinical trials.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PTEN (Phosphatase and tensin homolog) • DNMT3A (DNA methyltransferase 1) • PD-1 (Programmed cell death 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CD4 (CD4 Molecule) • PHLPP1 (PH Domain And Leucine Rich Repeat Protein Phosphatase 1) • VAV1 (Vav Guanine Nucleotide Exchange Factor 1) • HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • PHLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2)
    |
    PTEN mutation • TET2 mutation
    9ms
    Study on the role of miR-10b-3p as SASP in exosomes of premature senescent hepatocytes induced by hexavalent chromium. (PubMed, Ecotoxicol Environ Saf)
    This suppression led to lower levels of p27, FOXO3a and p21, thereby enhancing the proliferation of HCC cells by relieving the negative regulatory mechanisms of the cell cycle. This research offers significant understanding into the oncogenic pathways induced by Cr(VI), and provides laboratory evidence for mechanistic studies targeting hepatic carcinoma associated with Cr(VI) exposure.
    Journal
    |
    FOXO3 (Forkhead box O3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • MIR10B (MicroRNA 10b) • PHLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2)
    1year
    Circular RNA circPHLPP2 promotes tumor growth and anti-PD-1 resistance through binding ILF3 to regulate IL36γ transcription in colorectal cancer. (PubMed, Mol Cancer)
    Overall, our findings reveal a novel mechanism by which circRNA regulates CRC immune evasion. circPHLPP2 may serve as a prognostic biomarker and potential therapeutic target for CRC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker • Circular RNA
    |
    IFNG (Interferon, gamma) • GZMB (Granzyme B) • HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • PHLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2)
    over1year
    Hypoxic glioma-derived exosomal miR-25-3p promotes macrophage M2 polarization by activating the PI3K-AKT-mTOR signaling pathway. (PubMed, J Nanobiotechnology)
    Our study reveals that miR-25-3p from hypoxic glioma cells is delivered to macrophages via exosomes as a mediator, promoting M2 polarization of macrophages through the miR-25-3p/PHLPP2/PI3K-AKT signaling pathway. This study suggests that targeted interventions to modulate miR-25-3p expression, transmission, or inhibition of PI3K-AKT pathway activation can disrupt the immune-suppressive microenvironment, providing a novel approach for immunotherapy in gliomas.
    Journal • IO biomarker
    |
    MIR25 (MicroRNA 25) • HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • PHLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2)
    over2years
    Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma (ASH 2023)
    Low mRNA expression of PHLPP2 predicted poor prognosis (p=.03) and engineered PHLPP2 loss showed enhanced PI(3)K activation and FOXO1 inactivation in CD4+ T-cells in-vitro. Thus, we defined the genomic landscape for AITL, which is largely characterized by epigenetic alterations, TCR signaling and PI3K/AKT dysregulation, which may be amenable for therapeutic targeting.
    IO biomarker • Omic analysis
    |
    PTEN (Phosphatase and tensin homolog) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CD20 (Membrane Spanning 4-Domains A1) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • JAK3 (Janus Kinase 3) • RHOA (Ras homolog family member A) • CD68 (CD68 Molecule) • PHLPP1 (PH Domain And Leucine Rich Repeat Protein Phosphatase 1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • VAV1 (Vav Guanine Nucleotide Exchange Factor 1) • HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • PHLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2)
    |
    IDH2 mutation • DNMT3A mutation • TET2 mutation • KMT2D mutation • JAK3 mutation • IDH2 R172 • RHOA G17V
    over2years
    PHLPP2: A Prognostic Biomarker in Adenocarcinoma of the Rectum. (PubMed, Turk J Gastroenterol)
    PHLPP2 expression may serve as a READ-specific prognostic biomarker and is involved in the PI3K-Akt signaling pathway.
    Journal
    |
    HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • PHLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2)
    over2years
    LncRNA SLC7A11-AS1 promotes the progression of hepatocellular carcinoma by mediating KLF9 ubiquitination. (PubMed, Neoplasma)
    Eventually, rescue experiments revealed that KLF9 knockdown abolished SLC7A11-AS1 silencing-mediated suppression of HCC progression in vivo and in vitro. Our results unveiled that m6A-modified SLC7A11-AS1 promoted HCC progression by regulating the STUB1/KLF9/PHLPP2/AKT axis, indicating that targeting SLC7A11-AS1 might alleviate HCC progression.
    Journal
    |
    SLC7A11 (Solute Carrier Family 7 Member 11) • HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • METTL3 (Methyltransferase Like 3) • PHLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2)
    over2years
    PHLPP2 Enhances Anti-tumor Immunity by Promoting M1 Polarization of Macrophages via STAT3-related Pathway in NSCLC (IASLC-WCLC 2023)
    The present study suggests that the expression of PHLPP2 in lung adenocarcinoma cells could promote the polarization of anti-tumor M1 type macrophages via STAT3-related immune signaling pathways.
    IO biomarker
    |
    CD68 (CD68 Molecule) • PHLPP1 (PH Domain And Leucine Rich Repeat Protein Phosphatase 1) • MRC1 (Mannose Receptor C-Type 1) • HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2) • PHLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2)
    |
    STAT3 expression